human leukocyte antigen-DR by flow cytometry. Real-time quantitative RT-PCR also revealed positive for minor bcr/abl transcript. Under the diagnosis of Ph+ ALL, induction chemotherapy containing imatinib was started. The patient achieved complete molecular remission in the bone marrow. After imatinib administration (600 mg/day) from day 8 of induction therapy, the left testicular tumor started to decrease in size, but magnetic resonance imaging showed only 50% reduction ( Figure  1A and B) . In December 2008, orchiectomy was carried out for diagnostic purpose. The specimen was pathologically confirmed as pure testicular seminoma without leukemic cell infiltration ( Figure 1C ). Moreover, it was strongly positive for KIT by immunohistochemistry ( Figure 1D ). In March 2009, the patient underwent myeloablative cord blood transplantation (CBT) following two courses of consolidation therapy containing imatinib. During follow-up 6 months after CBT, no recurrence in Ph+ ALL, as well as KIT-positive seminoma, were noted.
KIT expression is commonly seen in testicular seminoma, wherein, approximately a quarter of cases has activating mutations in the kinase domain, exon 17 [1, 2] . Although a tyrosine kinase inhibitor for KIT, such as imatinib, is expected to be an ideal molecular targeting drug for testicular seminoma, as well as for GIST, the clinical efficacy remains to be clarified. The KIT-mediated tumorigenesis and the sensitivity to imatinib might depend not only on the presence and/or type of activating mutations but also on other mechanisms, such as an autocrine/paracrine loop [3] . In this case, any known mutations in the KIT could not be Annals of Oncology letters to the editor detected. Currently, imatinib is being examined for refractory KIT-positive germ-cell tumors in a salvage setting with or without chemotherapy after the third line [4, 5] . To date, orchiectomy followed by either adjuvant irradiation or single-dose carboplatin is the standard treatment of stage I testicular seminoma. The present case has raised a possibility that imatinib might be useful for stage I KIT-positive seminoma as neoadjuvant and adjuvant therapies for orchiectomy. Further randomized controlled trials are necessary to confirm this alternative strategy. 
